Clinical trials: Lung Cancer Stage I
Advanced Non Small Cell Lung Cancer
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
- Trial name
- NCT02143466
- Testing
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- Where
- 42 sites in United States, Canada and 6 more
- Volunteers
- 344 people
- Sponsor
- AstraZeneca
Melanoma, Liver Cancer
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
- Conditions
- Melanoma, Liver Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT01935453
- Testing
- Recombinant hGM-CSF Herpes Simplex Virus Injection
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- OrienGene Biotechnology Ltd.
Advanced Malignancies, Non-small Cell Lung Cancer
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
- Trial name
- NCT00975767
- Testing
- MGCD265+erlotinib, MGCD265+docetaxel
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- Mirati Therapeutics Inc.
Lung Cancer, Breast Cancer
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced…
- Conditions
- Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- NCT00096707
- Testing
- 2-deoxy-D-glucose (2DG)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Threshold Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Investigate the effect of multiple oral doses of nintedanib on the single dose kinetics of a combination of ethinylestradiol and levonorgestrel (Microgynon®)
- Trial name
- NCT02751385
- Testing
- Microgynon, Nintedanib
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Lung Cancer, Lung Cancer Stage I
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing…
- Conditions
- Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II
- Trial name
- NCT03290534
- Testing
- CivaSheet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CivaTech Oncology
Non Small Cell Lung Cancer, Lung Cancer
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
A study to measure the safety and effectiveness of S-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
- Trial name
- NCT00078390
- Testing
- S-3304, Chemo-irradiation
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Shionogi
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Non-small Cell Lung Cancer, Prostate Cancer
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen…
- Conditions
- Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer, Transitional Cell Carcinoma
- Trial name
- NCT03927573
- Testing
- GEM3PSCA
- Where
- 5 sites in Germany
- Volunteers
- 23 people
- Sponsor
- AvenCell Europe GmbH
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
AC0010MA is a new, irreversible, Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor. Aim at local advanced or metastatic non-small cell lung cancer patients with EGFR mutation or T790M…
- Trial name
- NCT02448251
- Testing
- AC0010MA
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 28 people
- Sponsor
- ACEA Therapeutics, Inc.
Carcinoma, Small Cell
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
- Trial name
- NCT00537511
- Testing
- Pomalidomide, Cisplatin, Etoposide
- Where
- 6 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Celgene
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Non-Small Cell Lung Cancer
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in…
- Trial name
- NCT02486718
- Testing
- Atezolizumab, Cisplatin, Vinorelbine
- Where
- 216 sites in United States, Australia and 20 more
- Volunteers
- 1,280 people
- Sponsor
- Hoffmann-La Roche
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
Non-small Cell Lung Cancer Metastatic
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT…
- Trial name
- NCT01935154
- Testing
- Vx-001
- Where
- 70 sites in Czechia, France and 6 more
- Volunteers
- 221 people
- Sponsor
- Vaxon Biotech
Carcinoma, Non-small Cell Lung
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
- Trial name
- NCT00729742
- Testing
- Comparator: erlotinib + dalotuzumab, Comparator: erlotinib monotherapy
- Volunteers
- 49 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer
This is a multicenter, open-label, Phase 1 clinical study to evaluate the efficacy and safety of HS-20093 combination therapy in subjects with advanced or metastatic non-small cell lung cancer without actionable genomic…
- Trial name
- NCT07899086
- Testing
- HS-20093, Ivonescimab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Hansoh BioMedical R&D Company